The Medical Letter on Drugs and Therapeutics
Doripenem (Doribax) - A New Parenteral Carbapenem
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Doripenem (Doribax – Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of complicated intra-abdominal and urinary tract infections. Use of doripenem for treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is still under FDA review.

ANTIBACTERIAL ACTIVITY — Like imipenem and meropenem, doripenem is active against a broad range of gram-positive, gram-negative and anaerobic pathogens.1 In vitro, it is more active than imipenem and meropenem against Pseudomonas aeruginosa2 and is active against some pseudomonal isolates resistant to the other carbapenems3,4; the clinical significance of this in vitro activity is unknown. Carbapenems have little or no activity ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Doripenem (Doribax) - A New Parenteral Carbapenem
Article code: 1278a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian